Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy When Treating Anxiety Disorders? A Meta-Analytic Review

Department of Psychology, Boston University.
International Journal of Cognitive Therapy (Impact Factor: 0.98). 02/2009; 2(2):160-175. DOI: 10.1521/ijct.2009.2.2.160
Source: PubMed


In order to examine the benefit of adding pharmacotherapy to cognitive-behavioral therapy (CBT) for anxiety disorders, we searched for studies comparing CBT plus pharmacotherapy and CBT plus pill placebo for adults meeting DSM-III-R or DSM-IV diagnostic criteria for an anxiety disorder between the 1st available year and July 1, 2008. Of 874 studies that were initially considered, 11 studies were identified, representing 471 patients with post-acute completer data and 236 participants with follow-up completer data. CBT plus pharmacotherapy was generally more effective than CBT plus placebo at post-treatment for measures of anxiety disorder severity (Hedges' g = 0.59, 95% confidence interval: 0.29-0.90) and treatment response (OR: 1.95, 95% confidence interval: 1.25-3.03), but not at 6-month follow-up. Despite the relatively small number of studies, the fail-safe N suggested that the results are reliable. The largest effect sizes at post-treatment were found for panic disorder and generalized anxiety disorder. No differences were observed between self-report and clinician-administered measures. The reported effect sizes linearly decreased with publication year. In sum, there is preliminary evidence to suggest that adding pharmacotherapy to CBT is a useful short-term treatment strategy at least for some of the anxiety disorders.

Download full-text


Available from: Stefan G Hofmann, Oct 14, 2014
  • Source
    • "d that the addition of imipramine to CBT treatment reduced the long-term durability of CBT. Furthermore, a meta-analysis comparing CBT plus pharmacotherapy versus CBT plus placebo across a range of anxiety disorders found that although CBT plus pharmacotherapy was superior at post-treatment, the treatments were comparable at follow-up assessments (Hofmann e tal. 2009). These findings indicate that the addition of adjunct treatments to CBT does not improve, and may be detrimental to, CBT's long-term efficacy. It is noteworthy that our results show change over acute treatment in both dysfunctional attitudes and negative automatic thoughts, but not rumination or distraction tendency , as potential mech"
    [Show abstract] [Hide abstract]
    ABSTRACT: Efficacious treatments for seasonal affective disorder include light therapy and a seasonal affective disorder-tailored form of cognitive-behavioral therapy. Using data from a parent clinical trial, these secondary analyses examined the relationship between cognitive change over treatment with cognitive-behavioral therapy, light therapy, or combination treatment and mood outcomes the next winter. Sixty-nine participants were randomly assigned to 6-weeks of cognitive-behavioral therapy, light therapy, or combination treatment. Cognitive constructs (i.e., dysfunctional attitudes, negative automatic thoughts, and rumination) were assessed at pre- and post-treatment. Dysfunctional attitudes, negative automatic thoughts, and rumination improved over acute treatment, regardless of modality; however, in participants randomized to solo cognitive-behavioral therapy, a greater degree of improvement in dysfunctional attitudes and automatic thoughts was uniquely associated with less severe depressive symptoms the next winter. Change in maladaptive thoughts during acute treatment appears mechanistic of solo cognitive-behavioral therapy’s enduring effects the next winter, but is simply a consequence of diminished depression in light therapy and combination treatment.
    Cognitive Therapy and Research 12/2013; 37(6). DOI:10.1007/s10608-013-9561-0 · 1.70 Impact Factor
  • Source
    • "For example, it may be possible that anxiolytic pharmacotherapy increases the ability for CBT principles to be learned. However, such combination strategies typically yield disappointing results as shown in a meta-analytic review that examined all randomized placebo-controlled clinical trials comparing combination treatment (i.e., CBT plus pharmacotherapy) with CBT plus placebo across the anxiety disorders [9]. Although there are some studies that seem to suggest that medications can support CBT, the general results revealed only modest benefits of combined interventions immediately following treatment and for only some anxiety disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this review is to examine the clinical studies on d-cycloserine, a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure procedures during cognitive behavioral therapy for anxiety disorders. Although cognitive behavioral therapy and anxiolytic medications are more effective than placebo for treating anxiety disorders, there is still considerable room for further improvement. Traditional combination strategies typically yield disappointing results. However, recent studies based on translational research have shown promise to augment the neural circuitry underlying fear extinction with pharmacological means. We discuss the current state of the literature, including inconsistencies of findings and issues concerning the drug mechanism, dosing, and dose timing. D-cycloserine is a promising combination strategy for cognitive behavioral therapy of anxiety disorders by augmenting extinction learning. However, there is also evidence to suggest that d-cycloserine can facilitate reconsolidation of fear memory when exposure procedures are unsuccessful.
    Biology of Mood and Anxiety Disorders 06/2013; 3(1):11. DOI:10.1186/2045-5380-3-11
  • Source
    • "Studies examining combination therapy, in which CBT is combined with anxiolytic medication, have also led to disappointing results (Otto, McHugh et al., 2010). A meta-analytic review comparing the efficacy of CBT plus medication versus CBT plus placebo found that combining these treatment modalities may be a useful short-term strategy for some anxiety disorders but not others, and is generally not a viable approach as a long-term strategy (Hofmann et al., 2009). Recent efforts have therefore turned to a different model of combination therapy, in which CBT is enhanced by pharmacologic agents that are known to impact some of the core learning processes involved in CBT, in particular extinction learning. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Traditional treatments for anxiety disorders include cognitive-behavioral therapy and anxiolytic medications. Although these treatments are more effective than placebo, there is still considerable room for further improvement. Unfortunately, combining these different modalities is generally not substantially better than monotherapies. Recently, researchers have turned their attention toward translating preclinical research on the neural circuitry underlying fear extinction to clinical applications for the treatment of anxiety disorders with the goal to augment the learning process during exposure-based procedures with cognitive enhancers. This review examines d-cycloserine, cortisol, catecholamines, yohimbine, oxytocin, modafinil, as well as nutrients and botanicals as agents to augment treatment for anxiety disorders. D-cycloserine shows the most empirical support. Other promising agents include cortisol, catecholamines, yohimbine, and possibly oxytocin. Less support comes from studies that examined nutrients and botanicals, such as caffeine, nicotine, and omega-3 fatty acid. Limitations of the exiting literature and future research directions are discussed.
    Restorative neurology and neuroscience 03/2013; 32(1). DOI:10.3233/RNN-139002 · 2.49 Impact Factor
Show more